308 related articles for article (PubMed ID: 33736856)
21. Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for
Navitski A; Al-Rawi DH; Liu Y; Rubinstein MM; Friedman CF; Rampal RK; Mandelker DL; Cadoo K; O'Cearbhaill RE
Gynecol Oncol Rep; 2021 Nov; 38():100873. PubMed ID: 34926756
[TBL] [Abstract][Full Text] [Related]
22. Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience.
Smith RE
Clin Breast Cancer; 2003 Oct; 4(4):273-9. PubMed ID: 14651772
[TBL] [Abstract][Full Text] [Related]
23. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).
Freedman RA; Seisler DK; Foster JC; Sloan JA; Lafky JM; Kimmick GG; Hurria A; Cohen HJ; Winer EP; Hudis CA; Partridge AH; Carey LA; Jatoi A; Klepin HD; Citron M; Berry DA; Shulman LN; Buzdar AU; Suman VJ; Muss HB
Breast Cancer Res Treat; 2017 Jan; 161(2):363-373. PubMed ID: 27866278
[TBL] [Abstract][Full Text] [Related]
24. Report of the Cancer Therapy Evaluation Program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins.
Smith MA; Rubinstein L; Cazenave L; Ungerleider RS; Maurer HM; Heyn R; Khan FM; Gehan E
J Natl Cancer Inst; 1993 Apr; 85(7):554-8. PubMed ID: 8455202
[TBL] [Abstract][Full Text] [Related]
25. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review.
Lyman GH; Dale DC; Wolff DA; Culakova E; Poniewierski MS; Kuderer NM; Crawford J
J Clin Oncol; 2010 Jun; 28(17):2914-24. PubMed ID: 20385991
[TBL] [Abstract][Full Text] [Related]
26. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.
Carney DA; Westerman DA; Tam CS; Milner A; Prince HM; Kenealy M; Wolf M; Januszewicz EH; Ritchie D; Came N; Seymour JF
Leukemia; 2010 Dec; 24(12):2056-62. PubMed ID: 20962860
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of epigenetic agents for older patients with acute myeloid leukemia and myelodysplastic syndrome in randomized controlled trials: a systematic review and network meta-analysis.
Oh S; Kim E
Clin Exp Med; 2023 Oct; 23(6):2705-2714. PubMed ID: 36964818
[TBL] [Abstract][Full Text] [Related]
28. Association between meat, fish, and fatty acid intake and incidence of acute myeloid leukemia and myelodysplastic syndrome: the Japan Public Health Center-based Prospective Study.
Shimomura Y; Sobue T; Zha L; Kitamura T; Iwasaki M; Inoue M; Yamaji T; Tsugane S; Sawada N
Environ Health Prev Med; 2023; 28():19. PubMed ID: 36878605
[TBL] [Abstract][Full Text] [Related]
29. Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.
Rosenstock AS; Niu J; Giordano SH; Zhao H; Wolff AC; Chavez-MacGregor M
Cancer; 2018 Mar; 124(5):899-906. PubMed ID: 29236294
[TBL] [Abstract][Full Text] [Related]
30. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
[TBL] [Abstract][Full Text] [Related]
31. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL;
Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262
[TBL] [Abstract][Full Text] [Related]
32. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
Verma D; O'Brien S; Thomas D; Faderl S; Koller C; Pierce S; Kebriaei P; Garcia-Manero G; Cortes J; Kantarjian H; Ravandi F
Cancer; 2009 Jan; 115(1):101-6. PubMed ID: 19090005
[TBL] [Abstract][Full Text] [Related]
33. Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis.
Suh YJ; Lee B; Kim K; Jeong Y; Choi HY; Hwang SO; Kim YB
BMC Cancer; 2022 Mar; 22(1):346. PubMed ID: 35354431
[TBL] [Abstract][Full Text] [Related]
34. Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005.
Kaplan HG; Malmgren JA; Atwood MK
BMC Cancer; 2011 Jun; 11():260. PubMed ID: 21693006
[TBL] [Abstract][Full Text] [Related]
35. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
[TBL] [Abstract][Full Text] [Related]
36. Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials.
Castellano G; Corti C; Boldrini L; Gervaso L; Criscitiello C; Curigliano G
Cancer Treat Rev; 2023 Sep; 119():102601. PubMed ID: 37473517
[TBL] [Abstract][Full Text] [Related]
37. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
[TBL] [Abstract][Full Text] [Related]
38. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome.
Borthakur G; Estey AE
Curr Oncol Rep; 2007 Sep; 9(5):373-7. PubMed ID: 17706165
[TBL] [Abstract][Full Text] [Related]
39. Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data.
Zhao Q; Ma P; Fu P; Wang J; Wang K; Chen L; Yang Y
Front Pharmacol; 2022; 13():912256. PubMed ID: 35784751
[No Abstract] [Full Text] [Related]
40. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
